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Context – Serological methods have become to use first turn before all methods of clinical laboratory diagnostics, and they stay 
remain extremely relevant to the present day. Serologic methods are used for diagnostics as infectious (bacterial, viral, fungal, parasitic), 
and non-infectious (oncological, endocrine, allergic) diseases. A significant proportion of diagnostic examinations carried out by the 
laboratory service relates precisely to serological tests. Serologic methods remain an indispensable part of ensuring the sanitary and 
epidemiological well-being of each country. Development of serological diagnostics products is the subject of immunobiotechnology – a 
section of biotechnology, which aims to create diagnostic and immune preparations for the diagnosis, treatment and prevention of human 
and animal diseases. Products for serological diagnostics belong to a class of medical devises. Obviously, the problem solved by such 
medical products is extremely responsible, because the health and life of the patient depends on the correctness of the outcome of the 
laboratory study. That is why, at the present stage, special attention is paid to the quality of medical devises for in vitro diagnostics, 
which, in turn, is connected with questions of standardization and technical regulation. A review of the medical and biological 
characteristics of the main common serological methods of diagnosis was made. The modern scientific and regulatory requirements for 
the analytical quality of products for serological in vitro diagnostics were summarized. 
Keywords – serological methods, in vitro diagnostics, medical devises, analytical quality. 
I. INTRODUCTION 
William Osler, a prominent Canadian physician of the 
19th century believed that “medicine is a 
scienceofuncertainty and an art of probability; one of the 
main causes of this uncertainty is increasing variability of 
manifestations of any disease” (1). A branch of medical and 
biological sciences formed in the first half of the 20th 
century, clinical-laboratory diagnostics, was aimed to 
minimize the scope of “uncertainty” when establishing the 
diagnosis. At present, clinical laboratory diagnostics 
combined laboratory methods of objective chemical and 
morphological analysis of biological materials (fluids, 
tissues, cells) of a human body. Such objective testing 
enables to carry out assessment of the condition of body 
organs, physiological systems and their spare capacities; to 
identify deviations from normal state and pathological 
disorders in activity of organs, human body systems; to 
establish diagnoses of diseases and perform laboratory 
control over pathological process dynamics, treatment and 
rehabilitation results. Meeting the challenges facing modern 
medical science and practice is impossible without patient’s 
laboratory examination [1-3]. 
Serological diagnostics methods were among the first 
ones suggested and implemented into practical medicine 
from the whole complex of clinical laboratory diagnostics 
methods; they still remain highly urgent nowadays. 
Serological methods are used for diagnostics of both 
infectious (bacterial, viral, fungal, and parasitic) and non-
infectious (oncologic, endocrine, allergic) diseases. 
Considerable portion of diagnostic examinations performed 
by laboratory service belong to serological tests. 
Serological methods remain an indispensable component of 
assurance of sanitary-epidemiological welfare of our 
country [1, 4-5]. 
It is worth mentioning that the range of methods and 
technologies used has greatly expanded from the time 
elapsed since implementation of laboratory examination of 
patients for diagnostic purposes. Advance in science and 
technology in the second half of the 20th century has 
perceivably increased the capabilities of laboratory 
diagnostics – almost all chemical and cellular components 
of biological materials have become accessible for 
assessment, and available methods, technologies, and 
equipment allowed characterizing the condition of body 
organs and systems with great precision. A whole branch of 
research-and-production activities involved in development 
and manufacture of devices for clinical laboratory 
diagnostics has been formed [6-7]. Appropriate scientific 
developments are the subjects of biotechnology – science 
and industry, which emerged in the second half of the 20th 
century, and aims to create useful products, drugs and 
technologies on the basis of biosynthesis or 
biotransformation processes. Objects in biotechnology are 
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biological agents – viruses, prokaryotes, cells and tissues of 
plants, humans and animals, their components and 
extracellular substances used in biological processes. The 
formation of the modern biotechnology industry took place 
at the junction of fundamental biological sciences 
(molecular and cellular biology, biochemistry, 
microbiology, virology, genetics) and engineering and 
technological disciplines. Development of serological 
diagnostic tools is the subject of immune biotechnology – a 
section of biotechnology, which aims to create diagnostic 
and immune products for the diagnosis, treatment and 
prevention of human and animal diseases [1, 8-9]. 
Thus, the purposes of the work were a comparative 
analysis of serological methods used in immune 
biotechnology and generalization of various regulatory 
approaches to their analytical standardization. 
II. COMPARATIVE CHARACTERIZATION OF 
SEROLOGICAL METHODS: MEDICAL AND 
BIOTECHNOLOGICAL ASPECTS 
Immune reactions are used in diagnostic and 
immunological tests. The methods applied for this purpose 
are serological ones, i.e., methods for identification of 
antibodies and antigens using “antigen-antibody” reactions 
in blood serum and other body fluids and tissues. 
Identification of antibodies against certain antigens in 
patient’s blood serum allows performing diagnostics of 
diseases of both infectious and non-infectious origin. 
Serological tests are used for identification of microbial 
antigens, various bioactive substances, blood groups, tissue 
and tumor antigens, immune complexes, cellular receptors 
etc. 
Agglutination reaction. Agglutination reaction is 
adhesion of corpuscles (bacteria, erythrocytes etc.) by 
antibodies in the presence of electrolytes (sodium chloride). 
Agglutination reaction is manifested in the form of flocks 
or sediment comprised of corpuscles (e.g. bacteria) 
“agglutinated” by antibodies. Such interaction results in 
formation of particles – agglomerates, which are 
precipitated (agglutinate). Agglutination reaction can 
involve bacteria, protozoa, fungi, yeasts, Rickettsia, 
erythrocytes and other cells, either living or killed. The 
reaction occurs in two phases: the first one is specific 
binding of antigen and antibody, and the second one is non-
specific (formation of visible agglutinate). Microorganisms 
found in agglutinate remain alive, yet they lose their 
mobility. 
At present, AR is used for identification of antibodies in 
blood serum of patients, e.g. in brucellosis (Wright's test, 
Hedelson's reaction), typhoid fever and paratyphoid fevers 
(Widal's test) and other infectious diseases; identification of 
causative agent isolated from a patient; determination of 
blood groups using monoclonal antibodies against 
erythrocyte alloantigens. 
AR is widely used for serological diagnostics of 
infectious diseases and determination of antigenic structure 
of isolated microorganisms. In order to determine antigenic 
structure of a causative agent isolated from the body of a 
patient or a carrier, specific immune serum is used, which is 
produced via immunization of animals (e.g. rabbit, donkey, 
or sheep) with certain microorganisms. Microbial 
identification is performed through agglutination reaction 
on glass with adsorbed or monoreceptor serums, or in test 
tubes with species-specific agglutinated serums. Adsorbed 
serums contain antibodies only against antigens specific for 
this particular microbe, and monoreceptor ones contain 
antibodies only against one specific antigen of a causative 
agent. Species-specific serums contain antibodies against 
all antigens of a certain microbial species [10-12]. 
Antibodies can be identified in patient’s blood serum using 
agglutination reaction in such diseases as typhoid fever and 
paratyphoid fevers (Widal's test), brucellosis (Wright's test), 
tularemia etc. [13-17]. 
Indirect hemagglutination reaction. Indirect 
hemagglutination reactions are based on the use of 
erythrocytes with adsorbed molecules of a known soluble 
specific substance involved in “antigen-antibody” reaction. 
In case of detection of antibodies, the relevant antigens 
are pre-adsorbed on erythrocytes, and the reaction itself is 
called indirect (passive) hemagglutination reaction (IHAR). 
Reverse indirect hemagglutination reaction (RIHAR), on 
the contrary, is intended for identification of antigens (or 
microorganisms themselves) and provides for preliminary 
adsorption of specific antibodies on the erythrocyte surface. 
Hemagglutination inhibition reaction (HAIR), when a virus 
isolated from a patient is neutralized with specific immune 
serum and then combined with erythrocytes is also used in 
serological tests. The absence of hemagglutination is 
indicative of the conformity between the virus and the 
immune serum used. 
Co-agglutination reaction (CAR) is close to IHAR. It is 
used for identification of antigens using antibodies bound 
with Staphylococcal protein A (so-called antibody 
diagnostic preparation) [18]. Protein A is known to have 
affinity for Fc fragment of IgG molecule of humans and 
certain animals [19, 20]. This peculiarity of the mentioned 
bacteria allows obtaining antibody-based Staphylococcal 
diagnostic preparations. They contain standard suspensions 
of bacterial cells loaded with antibodies which specifically 
react with antigenic determinants of examined infectious 
disease agents. CAR reaction results in formation of flocks 
comprised of Staphylococcal protein A, antibodies of 
diagnostic serum and the microorganism being identified. 
At present, various methods for production of 
erythrocytic diagnostic preparations have been developed, 
which differ in erythrocyte sensitization methods (using 
tannin, glutaraldehyde, chromic chloride, rivanol etc.), their 
affiliation with a certain species (human, sheep, chicken, 
turkey etc.), reaction preparation options (in microtitration 
plates, test tubes, capillaries) and accounting of results 
(visual, instrumental). 
IHAR has rather high sensitivity and specificity 
parameters, which stipulates for its broad use in diagnostics 
of infections caused by bacteria, Rickettsia, and protozoa. 
Erythrocytic Salmonella O-diagnostic preparation, 
representing a suspension of erythrocytes with adsorbed O-
antigens of various Salmonella groups on them, is used for 
IHAR preparation with patient’s serum when the clinical 
diagnosis of Salmonella infection needs to be specified. 
Erythrocytic Vi-diagnostic preparation represents 
erythrocytes sensitized with purified Vi-antigen of 
Salmonella typhi; it is used in IHAR for identification of 
typhoid fever bacteria carriage [21, 22]. Erythrocytic tests 
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for diagnostics of diphtheria, tetanus, schistosomiasis, 
influenza virus, chickenpox virus etc. have been developed 
and manufactured [23, 24]. CAR-based diagnostic 
preparations are used for identification of causative agents 
of genital herpes, Streptococcus infection, dermatoses, 
cattle pox etc. [18, 25, 26]. 
Precipitation reactions. Precipitation reaction in agar 
gel, or diffuse precipitation method, allows to study the 
composition of complex water-soluble antigen mixtures in 
detail. Gel (semi-liquid or denser agar) is used for the 
reaction preparation. Each component in antigen 
composition diffuses towards the relevant antibody at 
different rates. That is why complexes of different antigens 
and relevant antibodies are located at different sites of a gel 
plate, where precipitation lines are formed. Each of the 
lines conforms to a certain specific “antigen-antibody” 
complex. Precipitation reaction is typically carried out at 
room temperature. Besides usual linear immunodiffusion, 
which has no practical value at present, two most widely 
used modifications of the method are described: double 
radial immunodiffusion by О. Ouchterlony[27] and simple 
radial immunodiffusion by G. Mancini [28].  
Precipitation reaction is a very sensitive method, and it 
is used in studies of various protein and polysaccharide 
antigens in forensic practice – for determination of species 
of blood, sperm, serum stains present on underwear and 
various objects. This reaction can also be used for detection 
of various admixtures in milk, fish and meat products, 
identification of the nature of proteins in the composition of 
paints of the “old     masters” [29-30]. 
Neutralization reaction. Immune serum antibodies are 
capable of neutralizing the effect of microorganisms (in 
particular, viruses) or their toxins on sensitive cells and 
tissues, which is due to blocking of causative agent antigens 
with antibodies, i.e. their neutralization. This reaction is 
most frequently used in viral diseases either for detection of 
antibodies in patient’s blood or for identification of viruses 
isolated from patients. 
Virus neutralization reaction (NR) is based on the fact 
that specific antibodies bind antigenic determinants of 
surface viral proteins and prevent the virus adsorption on 
the sensitive host cell. As a result, the virus loses its ability 
to reproduction, which is confirmed by its inability to 
damage cells in in vitro system and cause diseases in 
sensitive animals. 
Cell cultures, chicken embryos, and laboratory animals 
(newborn or adult mice, hamsters) are used for 
determination of viral NR. 
A known virus-containing material (allantoic fluid of 
chicken embryos, cultural fluid etc.) is used for serological 
diagnostics of viral infections, i.e. establishment of the 
concentration of anti-viral antibodies in patient’s blood 
serum. The virus is titrated preliminarily. Virus titer is 
interpreted as its dose assuring 50 % biological effect – 
causing cytopathic effect (CPE) in 50 % of infected cell 
cultures (TCD50), or death or development of a disease in 
50 % of infected animals (LD50 or ID50). For NR 
preparation, 100 TCD50 of virus in equal volumes is added 
to subsequent dilutions of patient’s blood serums. After 
incubation of reagents at temperature 37 °С for 1-2 hours, 
their mixtures are added to a sensitive system (a suspension 
of susceptible cells, chicken embryos, or laboratory 
animals). The results are calculated after the relevant 
period. 
Delay in viral cytopathic activity in cell culture with 
addition of the mixture of virus and patient’s serum (in the 
presence of degenerative changes in cells in control test 
tubes where only virus was added) is indicative of the 
presence of antiviral antibodies in the patient’s body. 
Absence or decrease in number (versus the control) of 
diseased and dead animals or chicken embryos is indicative 
of the same fact. 
One NR modification is color test. It is based on the 
ability of cells cultures growing in vitro to decrease the 
nutrient medium pH due to accumulation of metabolic 
products and thus change the color of the medium 
containing an indicator phenol red from pink to yellow. 
Enteroviruses and some other viruses inhibit metabolism of 
infected cells and prevent the medium color change [10-12, 
30-32]. 
Complement fixation test. Complement fixation text 
(CFT) is based on the fact that when antigens and 
antibodies conform to each other, they form an immune 
complex to which complement is bound via antibody Fc 
fragment; thus, complement fixation via “antigen-antibody” 
complex occurs. Complement fixation occurs at the first 
reaction step upon formation of “antigen-antibody” 
complex; in this case, hemolysis of erythrocytes sensitized 
with antibodies will not occur (positive reaction). If an 
antigen and an antibody do not conform to each other (or 
antigen or antibodies are absent in the tested sample), the 
complement remains free and binds to “erythrocyte – anti-
erytrocytic complex” at the second step, causing hemolysis 
(negative reaction) [10-12]. CFT is used for detection of 
antibodies in patients’ blood serum in bacterial, viral, 
protozoal infections, as well as for identification and typing 
of viruses isolated from patients [30, 31].  
Antigens applicable for CFT are killed bacteria 
suspensions, extracts prepared from these suspensions, 
individual chemical microbial fractions. The main 
requirement to the antigen is the absence of inhibition of 
complement activity: it must not possess anti-
complementary properties. To identify these antigenic 
properties, the complement is additionally titrated in the 
presence of antigen used in the reaction. CFT is used in 
diagnostics of syphilis (Wassermann reaction), gonorrhea 
(Bordet-Gengou reaction), toxoplasmosis, Rickettsia and 
viral diseases [30, 31]. 
Immunofluorescence reaction. Immunofluorescence 
reaction (IFR) is based on “antigen-antibody” reaction, in 
which the antibody is marked with a certain fluorescent dye 
(fluorochrome). Upon formation of such complex, it can be 
identified using luminescent microscopy or other device 
capable to register the relevant signal [33]. Fluorescein 
isocyanate and isothiocyanate etc. are used as fluorescent 
tags. 
Immunofluorescence reaction (or fluorescent antibodies 
method) has two principal variants: direct and indirect. In 
the direct variant, specific immune serums labeled with 
fluorochromes raised against each type of test antigen are 
used for identification of different antigens. In this case, a 
large set of labeled antibodies is required, which can 
complicate the task a lot. In indirect IFR variant, only one 
immune serum is labeled with fluorescent tag – the one 
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raised against human or animal immunoglobulins, which is 
a donor of serum specific for the test antigen (in other 
words, anti-species serum with fluorescent tag). At the first 
IFR stage, interaction of relevant specific antibodies 
(immune serum) and antigen (tested causative agent) with 
formation of “antigen-antibody” complex occurs. At the 
following stage, anti-species immunoglobulins labeled with 
fluorochrome are attached to the formed complex [10-12]. 
IFR allows performing qualitative and quantitative 
identification of surface and intracellular antigens is 
samples of cellular suspensions (cell cultures, bacteria, 
mycoplasms, Rickettsia), samples of blood, bone marrow, 
alveolar swabs, thin tissue slices. The method allows 
carrying out detailed evaluation of biological samples for 
the presence of certain antigenic determinants, typical of 
certain causative agents or diseases, to perform quantitative 
assessment of both surface and intracellular proteins and 
receptors. Examinations and assessment can be performed 
either manually using fluorescent microscope or in 
automated mode using fluorescence-based flow cytometry 
device or microarray cytometers. The use of confocal 
microscope and robotized fluorescent microscope in 
combination with image processing software is possible. 
Currently available automated technologies allow analyzing 
several dozens of antigens in one sample using a set of 
various fluorescent markers in the format of high-
informative microscopy and cytometry and approximately 
two times lower maximum set of antigens using up-to-date 
flow cytometry or confocal microscopy. IFR has found 
wide use in serological diagnostics of infectious and 
oncologic diseases, fundamental and applied studies in 
microbiology, cellular biology, genetics, pharmacology etc. 
[29, 31, 34, 35].  
Enzyme immunoassay. Enzyme immunoassay (EIA) is 
an immunochemical method based on “antigen-antibody” 
reaction using antigens or antibodies labeled with enzyme. 
EIA preparation is not associated with potential hazard of 
radioactive contamination and handling of radioactive 
materials; the assay results can be determined visually. 
Reagents for EIA are relatively cheap and accessible. At the 
same time, EIA is non-inferior compared to RIA in terms of 
informative value, sensitivity, and reliability [36-38]. 
It should be mentioned that at present EIA is widely 
used not only in serological diagnostics of infectious and 
non-infectious diseases, but almost in all branches of 
biological and medical science. Such wide EIA prevalence 
is due to its several doubtless advantages over other 
serological methods. EIA is characterized by high 
sensitivity, specificity and reproducibility of results, 
easiness of execution, availability and stability of reagents, 
methodological flexibility (possibility of modifications), 
rapidness, and possibility of automation for large-scale 
tests. 
From the viewpoint of immunochemical reaction 
location, all enzyme immunoassay variants can be divided 
into homogeneous and heterogeneous ones. In the first case, 
there is no need to separate the components into different 
phases. In homogeneous analysis, the activity of enzyme 
linked with antibodies or antigen is essentially different 
from the activity of free enzyme. In heterogeneous 
methods, separation of reagent linked with enzyme is 
mandatory: the labeled reagent is fixed on a solid phase, 
after which measurement of its enzymatic activity is carried 
out (the free ligand with label is preliminarily removed 
from the reaction zone). This principal method modification 
has been called enzyme-linked immunosorbent assay 
(ELISA). ELISA is the main enzyme immunoassay type 
used for today. 
Irrespective of the assay modification, it provides for 
occurrence of three processes: immunochemical “antigen-
antibody” reaction, fixation of enzymatic tag to the formed 
complex and identification of such tag with one or another 
physical or physicochemical method. Based on this, the 
necessary ELISA elements are as follows: solid phase 
(immunosorbent) – special plates made of polymer material 
with absorbed antigens or antibodies on the bottom of the 
wells; test material (body biological fluids) containing a 
certain antigen or antibodies to it; reagent with a tag – 
antibodies or antigens conjugated with an enzyme; 
substrate-chromogenic mixture containing substances 
serving as a substrate for the enzyme used, and a 
chromogen capable to change its color as affected by an 
enzymatic reaction. If the reaction results are identified by 
other method than visual, a relevant device is additionally 
required for measurement of the test sample optical density 
change. 
A range of polystyrene plates for ELISA with different 
sorption characteristics are manufactured. Antigens used in 
EIA can be native, synthetic, or recombinant. Antibodies in 
immunosorbent or conjugate composition are typically 
monoclonal: due to limited capabilities to standardize 
polyclonal serums, their use in EIA is minor. Various 
bioorganic synthesis reactions with covalent bond 
formation are used to obtain conjugates or antibodies and 
antigens with enzymes; in some cases, the use of non-
covalent binding is possible via the application of high-
affinity interactions of various biomolecules. The main 
enzymatic tags in EIA are horseradish peroxidase (the most 
frequently used enzyme), alkaline phosphatase (an 
extremely stable and expensive enzyme), β-D-
galactosidase, glucose oxidase, and certain other [38, 39].  
Sometimes, signal amplification systems are used in 
ELISA; a classical example of such system is avidin-biotin 
system [38, 39]. It has been known for a long time that 
assurance of potent interaction between biotic and avidin, 
an egg albumen glycoprotein, requires only tetrahydro-
imidazole ring of vitamin. Thus, carboxylic group of 
valerianic acid residue in biotin can be modified, and thus 
active biotinylated derivatives can be obtained. In 
particular, biotin bound to macromolecule retains its ability 
to bind avidin active center (the binding constant is 1015 М-
1) [40]. As avidin molecule is comprised of four identical 
subunits, biotin residues of two different biotinylated 
proteins can be concomitantly bound to it. 
Practical use of avidin-biotin system is limited by high 
basic capacity of avidin and presence of carbohydrate 
residues in its molecule, which, in its turn, stipulates for 
high non-specific binding level. Another biotin-binding 
protein, called streptavidin, has been identified in bacteria 
Streptomyces avidinii[41]. Like egg albumen avidin, 
streptavidin also forms very potent and specific non-
covalent complex with biotin, and it is comprised of four 
identical subunits. Each subunit contains one biotin binding 
center. Unlike avidin, streptavidin is non-glycosylated and 
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has neutral pH level [40]. A study [42] describes two 
options of this type of analysis for identification of specific 
IgE-antibodies, serum concentration of which is extremely 
low. 
Enzyme-linked immunosorbent spot, ELISPOT assay is 
a modification of EIA method, and was initially developed 
for quantification of B-lymphocytes secreting specific 
antibodies [43]. Over time, ELISPOT was adapted to 
various tasks, first of all, for identification and 
quantification of cells producing cytokines. This method 
allows visualizing the product being secreted on the surface 
of an individual cell, activated or stimulated to an immune 
response. 
ELISPOT allows performing both qualitative (immune 
protein type) and quantitative (number of cells wit relevant 
molecular signal) evaluation. Modern ELISPOT test is 
carried out using so-called ELISPOT readers equipped with 
computed test results detection-visualization systems, 
which allows for maximum automation of the procedure 
and assurance of higher precision compared to manual 
examination. 
A specific EIA modification, hybridization-enzymatic 
assay (HEA), is used as one of the options for detection of 
polymerase chain reaction results.  
EIA also served as a basis for development of rapid tests 
(so-called dot blot ELISA), which provide for immersion of 
solid phase with the reagent into the test sample. Such test 
systems become more and more prevalent when rapid 
results of individual tests are needed in laboratory 
diagnostics of infectious diseases. For example, they can be 
used to identify markers of hepatitis B and C, HIV etc. [44, 
45]. 
Enzyme immunoassay has found extremely broad use in 
serological diagnostics of many infectious diseases (HIV 
infection/AIDS, viral hepatites, TORCH infections, 
sexually transmitted infections etc. [37, 46, 47]), oncologic 
diseases (identification of cancer markers [48]), endocrine 
disorders [49], allergy conditions [37, 50, 51], evaluation of 
the level of antibody-mediated and cellular immunity [52]. 
Immunochromatographic assay. Immunochromato-
graphic assay (ICA) is another immunochemical assay type, 
in which the test sample is applied on the surface of solid 
phase – membrane with pre-applied reagent, and the test 
result has the appearance of colored band. 
One of two ICA formats, direct or competitive method, 
is used depending on the tested analyte nature and 
peculiarities. In direct ICA (sometimes also called 
“sandwich” variant), conjugate of antibodies against the 
searched analyte with a certain tag, applied on the 
membrane, is used. Anti-species antibodies specific to 
primary antibodies (e.g. mouse monoclonal antibodies 
against human immunoglobulins) are immobilized on the 
membrane control line. Following application of the sample 
containing target analyte (e.g. viral antigen), the sample 
contact with the membrane bearing the conjugate results in 
the analyte binding with the conjugate of labeled 
antibodies. After that, the immune complex penetrates into 
the test zone, where it binds specific antibodies, forming the 
immune complex “antigen – conjugate of antibodies raised 
against the antigen and tag – secondary anti-species 
antibodies”. The excess of unbound conjugate binds anti-
species antibodies on the control line. Thus, identification 
of two lines on the test strip represents the positive test 
result. In the absence of analyte in the sample, the 
conjugate binds anti-species antibodies on the control line 
only, forming one band on the test strip. The similar 
principle can be applied for detection of specific antibodies 
as well. In this case, labeled antigen is immobilized in the 
test zone, and antibodies specific to this antigen are 
immobilized in the control zone. This ICA modification is 
used for identification of high molecular weight 
compounds, in particular, various serological markers of 
infectious diseases (antigens and specific antibodies). 
Competitive ICA has been used for detection of low 
molecular weight compounds. This method modification is 
based on the competition between the analyte and the 
immobilized analyte conjugate with protein carrier for the 
limited number of specific antibodies binding centers 
contained in the antibodies-tag conjugate. Application of 
analyte-containing sample results in the analyte binding 
with the tag on the membrane. Further, the immune 
complexes pass through the test zone, where the conjugate 
of analyte with protein carrier is immobilized. The immune 
complexes cannot bind this conjugate due to the steric 
difficulties: low molecular weight substances usually have 
one antigenic determinant and, consequently, the antibodies 
have one binding center with the antigen, which is already 
occupied with the analyte. Further, the immune complex 
binds anti-species antibodies located on the control line. As 
a result, the absence of stained band in the test zone and the 
presence of staining in the control zone are indicative of the 
fact that concentration of measured substance in the test 
sample exceeds its limit value for this test. In the absence of 
analyte in the sample, conjugate of antibodies with tag 
binds the conjugate of antigen with protein carrier 
immobilized in test line zone. Unbound conjugate of 
antibodies with tag reaches the control line zone and binds 
snit-species antibodies there. Thus, the presence of two 
stained lines (the test one and the control one) is used for 
detection of low molecular weight substances, in particular, 
metabolites of narcotic compounds [44, 53]. 
Immunoblot. Immunoblot (western blot, protein 
immunoblot) is a complex analytical method intended for 
detection of specific proteins, which provides for 
consecutive combination of the following methods: protein 
electrophoresis in polyacrylamide gel under denaturing 
conditions (usually in the presence of sodium dodecyl 
sulphate) or in native condition; transfer of proteins after 
their electrophoresis on a membrane (nitrocellulose, 
polyvinylidene fluoride) with following detection using 
specific antibodies (like EIA, IFR or RIA) [54, 55]. The 
method was suggested by a team headed by G. Stark, and 
conventionally called western blot as one of the tetrads of 
molecular biology methods intended for analysis of 
biomolecules: DNA (Southern blot), RNA (Northern blot) 
and post-translation protein modifications (Eastern blot) 
[56]. 
Immunoblot is used for analysis of proteins of both 
tissue and cellular origin. Several different methods are 
used for test sample preparation, which allow 
homogenizing it to the level of individual proteins. 
Essential aspect of these procedures is parallel protection of 
proteins to be examined from proteolytic enzymes which 
can be found in the initial sample, and from denaturing 
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factors of chemical and physical origin. Separation of test 
sample proteins using electrophoresis can be performed by 
their isoelectric point (рІ), molecular weight, or electric 
charge [57]. If a combination of two separation criteria is 
used, this is so-called two-dimensional electrophoresis. For 
further detection, proteins separated after electrophoresis 
are transferred with gel plate on a membrane using one of 
the following techniques: 1) membrane is placed on the gel, 
and a stack of filter paper is placed on the top, and the 
whole pile is transferred into a special buffer solution 
(protein transfer occurs as affected by capillary forces); 
2) combination of this technique with passage of electric 
current. After this “blotting”, proteins are fixed on a 
membrane with maintenance of their location. Essential 
step of assay required for assurance of successful detection 
is blocking of free membrane areas from non-specific 
interactions using an inert protein (e.g. bovine serum 
albumin) in the presence of detergent (e.g. Tween-20 or 
Triton Х-100). This procedure precludes any non-specific 
interactions of specific antibodies, involved in detection 
procedure, with the membrane (minimizes the possibility of 
false positive results). Specific antibodies interact with 
relevant antigens on membrane; detection is performed 
using secondary antibodies (e.g. anti-species) labeled with 
an enzyme, fluorochrome, or radioactive tag; further 
accounting of results is carried out in a manner similar to 
EIA, IFR or RIA (qualitative or quantitative). Evaluation of 
results can be performed using special software (31, 56). It 
should be mentioned that immunoblot is an extremely 
sensitive and specific method, which stipulates for its use in 
serological diagnostics as a confirmatory (verification) test, 
in particular, for establishment of final diagnosis of HIV 
infection/AIDS, hepatitis C, Lyme disease, bovine 
spongiform encephalopathy, feline acquired 
immunodeficiency syndrome etc. [58, 59]. 
III. BIOANALYTICAL STANDARDIZATION 
Fulfillment of targets of clinical laboratory diagnostics 
is performed using the relevant devices – a separate type of 
medical devices. Medical device for in vitro diagnostics 
(IVD) is interpreted as a medical device, in particular, 
reagent, calibrator, control material, kit, instrument, 
apparatus, equipment or system, whether used alone or in 
combination, intended by the manufacturer for use in vitro 
for examinations of specimens in laboratories, including 
blood and tissue samples derived exclusively from the 
human body, solely or principally for the purpose of 
providing information: concerning a physiological or 
pathological state; concerning a congenital abnormality; to 
determine the safety and compatibility of donations with 
potential recipients; to monitor therapeutic measures [10, 
11]. Development and manufacture of human and animal 
diseases diagnostic agents is one of the most important 
branches of immune and analytical                         
biotechnology [12, 13]. 
It should be mentioned that precision of test results 
obtained using IVD devices is extremely important, as it 
influences life and health of patients. In view of social 
value of quality of IVD devices and clinical laboratory 
diagnostics, an important general issue is scientific 
justification of bioanalytical standardization parameters of 
serological in vitro diagnostic devices (with following 
implementation of these requirements into national 
regulatory framework). Requirements of leading global 
pharmacopeias can be used for establishment of IVD 
devices standardization parameters only to a very limited 
extent. The existing standards specialized in medical 
devices and their manufacture – Directive 98/79/EC of the 
European Parliament and of the Council of 27 October 
1998 on in vitro diagnostic medical devices (IVDMD), 
ISO 13485:2016 “Medical devices. Quality management 
systems. Requirements for regulatory purposes”, and 
ISO/IEC 17025:2017 “General requirements for the 
competence of testing and calibration laboratories” 
formulate only general requirements to quality and safety of 
products. Table 1 generalizes the requirements of IVDMD 
pertaining to bioanalytical standardization of serological 
diagnostics devices. 
Table 1 
Requirements to Technical Regulation Pertaining to 
Bioanalytical Standardization of IVD Devices 
Characteristic Requirements to development and 
manufacture 
Safety Avoidance of risk for clinical condition 
or safety of consumers, users’ health, 
including due to safe design and 
construction. Assessment of potential risks 
versus benefits for patient or consumer. 
Provision of appropriate safety measures 
for avoidance of potential risks associated 
with the use of devices, which cannot be 
eliminated. 
Informing of users and consumers on 
potential risks associated with the use of 
devices, which cannot be eliminated via 
safety measures.  
Serviceabilit
y (quality) 
Achievement of operating characteristics 
(in particular, analytical and diagnostic 
sensitivity, analytical and diagnostic 
specificity, accuracy, repeatability, 
reproducibility), including control of 
possible hindrances, as well as detection 
limits. 
Traceability of accepted nominal values 
of calibrators and/or control materials has to 
be assured via the use of available reference 
measurement procedures and/or available 
reference materials (reference samples) of 
higher order. 
Stability Safety and quality of devices has to 
remain unaltered during the shelf life 
established by the manufacturer, and it may 
not become deteriorated to the level 
resulting in hazard to user’s health and 
safety when the device is exposed to stress 
which may occur under normal conditions 
of use. 
Characteristics and operating parameters 
may not become deteriorated during the use 
in accordance with intended purpose due to 
storage and transportation conditions. 
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For justification of IVD device standardization 
principles, it is expedient to use the recommendations on 
validation of analytical procedures and tests stated in SPU 
as input data. This expediency is due to the fact that these 
methodological approaches are scientifically justified, they 
are widely used in pharmaceutical branch, and they are 
harmonized with international guidance documents. At the 
same time, several peculiarities and differences of 
evaluation of pharmaceutical products and control of 
in vitro diagnostic agents should be formulated. In case of a 
medicinal product, active substance (active pharmaceutical 
ingredient) content in it is sufficient; this parameter is 
stipulated by a drug product manufacturing formula and it 
is strictly regulated (it typically has to be within 95% to 
105% of the nominal content).  In case of IVD device, 
content or biological activity of an individual component of 
the device (antigens, antibodies, their conjugates, bioactive 
substances of chemical or biological origin) has no 
principal value – the important factor is the ability of 
complex of the device ingredients (system) to identify a 
certain analyte, the content of which in the biological 
material test sample is not known in advance, in a reliable 
and precise manner. The essential difference between 
medicinal products and IVD devices is the mandatory 
content of controls (actually being internal standards of the 
system) in the composition of the latter, which have to be 
calibrated quantitatively (for quantitative test methods, e.g. 
for measurement of content of various immunoglobulin 
classes) or semi-quantitatively (for qualitative test methods, 
e.g. for identification of antibodies against hepatitis B virus 
surface antigen). 
We have to mention again the interrelation between the 
parameters of IVD devices bioanalytical standardization 
and analytical techniques validation procedure, as 
validation characteristics are actually standardization 
parameters. Thus, we suggest to proceed to justification of 
IVD devices validation characteristics. Based on 
recommendations of normative documents pertaining to 
medical devices [10, 11, 14, 15], medicinal products [16, 
17], literature data [19, 20] and our own experience in 
development of IVD devices [21, 22], we suggest the 
following approach to selection of validation characteristics 
for various IVD device types (table 2). Further, we suggest 
discussing each validation characteristic in a more detailed 
manner. 
Table 2.  
Validation characteristics for various IDV device 
types 
Characteristic 
IDV device type 
Quantitative 
Semi-
quantitative 
(qualitative) 
Accuracy + – 
Precision 
Repeatability 
Intermediate precision 
Reproducibility 
 
+ 
+ 
+ 
 
+ 
+ 
+ 
Specificity 
Diagnostic specificity 
Analytical specificity 
 
+ 
+ 
 
+ 
+ 
Sensitivity 
Diagnostic sensitivity 
  
Analytical sensitivity (limit 
of detection) 
+ 
+ 
+ 
– 
Linearity + – 
Range + – 
Remarks:  
“–“ – examination of the characteristic is not expedient; 
“+” – examination of the characteristic is expedient.  
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Серологічні методи використовувались в першу чергу перед усіма методами клінічної лабораторної діагностики, і вони 
залишаються надзвичайно актуальними і донині. Серологічні методи застосовуються для діагностики як інфекційних 
(бактеріальних, вірусних, грибкових, паразитарних), так і неінфекційних (онкологічних, ендокринних, алергічних) захворювань. 
Значна частка діагностичних обстежень, проведених лабораторною службою, стосується саме серологічних тестів. Серологічні 
методи залишаються невід'ємною частиною забезпечення санітарного та епідеміологічного благополуччя кожної країни. 
Розробка продуктів серологічної діагностики є предметом імунобіотехнології – розділу біотехнології, метою якого є створення 
діагностичних та імунних препаратів для діагностики, лікування та профілактики захворювань людини та тварин. Продукти для 
серологічної діагностики належать до класу медичних апаратів. Очевидно, що проблема, вирішена такими медичними 
препаратами, є надзвичайно важливою, адже від вірогідності результатів лабораторного дослідження залежить здоров’я та 
життя пацієнта. Ось чому на сучасному етапі особлива увага приділяється якості медичних пристроїв для діагностики in vitro, 
що, в свою чергу, пов'язано з питаннями стандартизації та технічного регулювання. У роботі здійснено огляд 
медикобіологічних характеристик основних поширених серологічних методів діагностики. Узагальнено сучасні наукові та 
нормативні вимоги до аналітичної якості продукції для серологічної діагностики in vitro. 
Ключові слова –  серологічні методи, in vitro діагностика, медичні апарати, аналітична якість. 
